Bristol immune drug shows strong effect in melanoma study

September 29, 2014 7:11 AM

15 0

MADRID (Reuters) - Bristol-Myers Squibb's immunotherapy drug Opdivo produced markedly improved response rates with fewer toxic side effects compared to chemotherapy in a major melanoma study, underscoring its potential as a new treatment option.

The data has been keenly awaited since this is the first presentation of results from a pivotal Phase III clinical trial of a promising new class of drugs designed to help the body's own immune system fight cancer.

Read more

To category page